KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Return on Capital Employed (2016 - 2025)

Sarepta Therapeutics has reported Return on Capital Employed over the past 15 years, most recently at 30.08% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 3723.0% year-over-year to 30.08%; the TTM value through Dec 2025 reached 30.08%, down 3723.0%, while the annual FY2025 figure was 27.32%, 3489.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 30.08% at Sarepta Therapeutics, down from 4.75% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 7.15% in Q4 2024 and troughed at 30.08% in Q4 2025.
  • A 5-year average of 13.31% and a median of 16.32% in 2022 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: soared 2109bps in 2024 and later crashed -3723bps in 2025.
  • Year by year, Return on Capital Employed stood at 18.75% in 2021, then decreased by -13bps to 21.26% in 2022, then soared by 50bps to 10.57% in 2023, then skyrocketed by 168bps to 7.15% in 2024, then plummeted by -521bps to 30.08% in 2025.
  • Business Quant data shows Return on Capital Employed for SRPT at 30.08% in Q4 2025, 4.75% in Q3 2025, and 0.04% in Q2 2025.